A Phase 2 interventional study of carfilzomib in Multiple Myeloma, sponsored by Amgen. Completed at 30 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-02.
Sponsored by Amgen · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 113 studies testing carfilzomib in Multiple Myeloma — 14 open to participants now, 39 under way, 7 of them phase 3. carfilzomib · Multiple Myeloma.
Among the 113 studies testing carfilzomib in Multiple Myeloma, this one is the 19th largest by enrollment, is one of 3 that started in 2007, is one of 50 in phase 2, and was the 3rd registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →14 of the 113 studies testing carfilzomib in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Natalie Callander · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, Australia, Brazil and 5 more countries
Ages 18+
Roswell Park Cancer Institute · Sites in United States
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
The First Affiliated Hospital of Soochow University · Sites in China
Ages 18+
By country, each count listing its studies:
carfilzomib: first FDA approval 2012 (KYPROLIS), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
113 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 45 · Phase 2 78 · Phase 3 15 · Phase 4 2
First in 2005; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 164 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 54 across the 113 interventional studies. Of the 67 that completed or were terminated, 46 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 113 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
43 studies in Multiple Myeloma by Amgen: none open now, none under way, none of them phase 3. Of 41 finished, 36 (88%) have results posted.
Among the 43 studies in Multiple Myeloma by Amgen, this one is the 14th largest by enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2007, is one of 10 in phase 2, and was the 7th registered.
Amgen’s Multiple Myeloma studies by the year they started, since 2005.
18 of the studies testing carfilzomib in Multiple Myeloma that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03729804Phase 3University of ChicagoCarfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA) | 2026-12-28 |
| NCT04096066Phase 3Fondazione EMN Italy OnlusA Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant | 2027-09-01 |
| NCT02659293Phase 3University of ChicagoTrial of Carfilzomib, Lenalidomide, Dexamethasone Versus Lenalidomide Alone After Stem-cell Transplant for Multiple Myeloma | 2027-11 |
| NCT04973605BeOne MedicinesA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | 2026-11 |
| NCT04883242University of WashingtonIsatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | 2026-12-31 |
Add all 18 to your calendar (.ics) → With an account.
Among the 113 studies testing carfilzomib in Multiple Myeloma, from their registry updates:
Among Amgen’s 43 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the best overall response rate, safety and tolerability of carfilzomib in patients with relapsed or refractory multiple myeloma.
Two groups of patients with multiple myeloma were initially studied: bortezomib-naïve and bortezomib-treated. Following Amendment 2, only bortezomib-naïve patients were enrolled. Study results were reported in 2 parts, depending on whether a patient received prior bortezomib.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Disease Related
Subjects must have , defined as one or more of the following:
Demographic
Laboratory
Ethical / Other
Exclusion Criteria:
Disease Related
Concurrent Conditions
Ethical / Other
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received carfilzomib 20 mg/m² intravenous (IV) injection on Days 1, 2, 8, 9, 15, and 16, in 28-day treatment cycles for a maximum of 12 cycles. Starting with Amendment 3, if all doses in Cycle 1 were well-tolerated the dose was escalated to 27 mg/m² IV for subsequent cycles.
Drug: carfilzomib
Intravenous (IV) injection over 2 to 10 minutes twice weekly for three weeks followed by 12 days of rest.
Also known as: PR-171, PR171, Kyprolis® (carfilzomib) for Injection
Best Overall Response Rate (ORR) in the Response Evaluable Subset Population
ORR is defined as the percentage of patients who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) determined by Independent Review Committee (IRC). Responses were assessed according to International Uniform Response Criteria for Multiple Myeloma, documented by 2 consecutive assessments made at any time before the start of new therapy. sCR: CR as defined below plus normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence. CR: absence of M-protein in serum and urine by immunofixation, disappearance of any soft tissue plasmacytomas, and ≤5% plasma cells in bone marrow. VGPR: serum and urine M-proteins detectable by immunofixation but not by electrophoresis or a ≥ 90% reduction in serum M-protein with urine M-protein level \< 100 mg/24 hours. PR: ≥ 50% reduction of serum M-protein and in urine of ≥ 90% or to \< 200 mg per 24 hours.
Time frame: Disease response was assessed on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12, and at End of Study, 30 days after last dose. Median duration of treatment was 100 days for Part 1 and 170 days for Part 2 participants.
Best Overall Response Rate (ORR) in the Response Evaluable Population
ORR is defined as the percentage of patients who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) determined by Independent Review Committee (IRC). Responses were assessed according to International Uniform Response Criteria for Multiple Myeloma, documented by 2 consecutive assessments made at any time before the start of new therapy. sCR: CR as defined below plus normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence. CR: absence of M-protein in serum and urine by immunofixation, disappearance of any soft tissue plasmacytomas, and ≤5% plasma cells in bone marrow. VGPR: serum and urine M-proteins detectable by immunofixation but not by electrophoresis or a ≥ 90% reduction in serum M-protein with urine M-protein level \< 100 mg/24 hours. PR: ≥ 50% reduction of serum M-protein and in urine of ≥ 90% or to \< 200 mg per 24 hours.
Time frame: Disease response was assessed on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12, End of Study, 30 days after last dose; median duration of treatment was 100 days for Part 1 and 170 days for Part 2 participants.
Clinical Benefit Rate (CBR)
Clinical Benefit Rate is defined as the percentage of participants with a best overall response of minimal response (MR) or better, i.e., a best overall response of sCR, CR, VGPR, PR, or MR. MR was defined as outlined by European Group for Blood and Marrow Transplantation (EBMT) criteria, defined as reduction of M-protein in serum of 25% to 49% and in urine of 50% to 89%, maintained for 6 weeks.
Time frame: Disease response was assessed on Day 15 of Cycle 1, Day 1 of Cycles 2 through 12, and at End of Study, 30 days after last dose. Median duration of treatment was 100 days for Part 1 and 170 days for Part 2 participants.
Duration of Response (DOR)
DOR is defined as the time from first evidence of PR or better to disease progression assessed by the IRC or death due to any cause. Patients lost to follow-up prior to disease progression or who were alive without disease progression before the analysis cutoff date were censored at the last disease assessment. Progressive disease was defined as any of the following: * An increase of M-protein in serum (absolute increase ≥ 0.5 g/dL) or urine (absolute increase ≥ 200 mg/24 hours) of \> 25% from the nadir (if not zero). * Percentage of plasma cells in bone marrow ≥ 10%. * New or increased size of bone lesions or new plasmacytomas. * Patients without measurable serum and urine M-protein: 25% increase from nadir in the difference between involved and uninvolved FLC levels and absolute increase \>10 mg/dL. * Development of hypercalcemia (corrected serum calcium \> 11.5 mg/dL) attributed solely to the proliferative disorder. Median DOR was estimated using Kaplan-Meier methods.
Time frame: Patients were followed for up to 2 years after study discontinuation. The data cutoff for the analysis is 30 November 2010 for Part 1 and 22 April 2011 for Part 2.
Time to Progression (TTP)
Time to Progression is defined as the time from the start of treatment to IRC-determined disease progression. Patients who were lost to follow-up prior to documentation of disease progression, or who died before documentation of disease progression or who were alive and did not have documentation of disease progression before the data analysis cut-off date were censored at the last disease assessment. Median TTP was estimated using the Kaplan-Meier method.
Time frame: Patients were followed for up to 2 years after study discontinuation. The data cutoff for the analysis is 30 November 2010 for Part 1 and 22 April 2011 for Part 2. Median follow-up time was 13.4 months for Part 1 and 11.5 months in Part 2.
Progression-free Survival (PFS)
Progression-free Survival (PFS) is defined as the time from start of treatment to IRC determined disease progression or death due to any cause. Patients who were lost to follow-up prior to documentation of disease progression and patients who were alive without disease progression before a data analysis cut-off date were censored at the last disease assessment. Median PFS was estimated using the Kaplan-Meier method.
Time frame: Patients were followed for up to 2 years after study discontinuation. The data cutoff for the analysis is 30 November 2010 for Part 1 and 22 April 2011 for Part 2. Median follow-up time was 13.4 months for Part 1 and 11.5 months in Part 2.
Overall Survival (OS)
Overall Survival is defined as the time from the start of study treatment to date of death due to any cause. Patients who were alive or lost to follow-up as of the data analysis cut-off date for the final OS analysis were censored at the date the patient was last known to be alive. Median OS was estimated using the Kaplan-Meier method.
Time frame: Patients were followed for up to 2 years after study discontinuation. The data cutoff for the analysis is 19 November 2012 for Part 1 and 07 January 2013 for Part 2. Median follow-up time was 19.1 months for Part 1 and 35.9 months in Part 2.
This study enrolled patients with multiple myeloma (MM) who had relapsed or refractory disease after at least 1 but no more than 3 prior therapeutic treatments or regimens. The first patient enrolled on 24 September 2007; the last patient was enrolled and received carfilzomib on 28 May 2009.
| Milestone | Part 1: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20/27 mg/m² |
|---|---|---|---|
| Started | 35 | 59 | 70 |
| Completed | 9 | 17 | 29 |
| Not completed | 26 | 42 | 41 |
| Withdrew: Progressive disease | 16 | 24 | 24 |
| Withdrew: Adverse event | 6 | 13 | 7 |
| Withdrew: Other | 3 | 3 | 4 |
| Withdrew: Withdrawal by subject | 1 | 2 | 6 |
ORR is defined as the percentage of patients who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) determined by Independent Review Committee (IRC). Responses were assessed according to International Uniform Response Criteria for Multiple Myeloma, documented by 2 consecutive assessments made at any time before the start of new therapy. sCR: CR as defined below plus normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence. CR: absence of M-protein in serum and urine by immunofixation, disappearance of any soft tissue plasmacytomas, and ≤5% plasma cells in bone marrow. VGPR: serum and urine M-proteins detectable by immunofixation but not by electrophoresis or a ≥ 90% reduction in serum M-protein with urine M-protein level \< 100 mg/24 hours. PR: ≥ 50% reduction of serum M-protein and in urine of ≥ 90% or to \< 200 mg per 24 hours.
| percentage of participants | Part 1: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20/27 mg/m² |
|---|---|---|---|
| Best Overall Response Rate (ORR) in the Response Evaluable Subset Population | 16.1 (5.45 to 33.73) | 39.6 (26.5 to 54.0) | 53.0 (40.3 to 65.4) |
ORR is defined as the percentage of patients who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) determined by Independent Review Committee (IRC). Responses were assessed according to International Uniform Response Criteria for Multiple Myeloma, documented by 2 consecutive assessments made at any time before the start of new therapy. sCR: CR as defined below plus normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence. CR: absence of M-protein in serum and urine by immunofixation, disappearance of any soft tissue plasmacytomas, and ≤5% plasma cells in bone marrow. VGPR: serum and urine M-proteins detectable by immunofixation but not by electrophoresis or a ≥ 90% reduction in serum M-protein with urine M-protein level \< 100 mg/24 hours. PR: ≥ 50% reduction of serum M-protein and in urine of ≥ 90% or to \< 200 mg per 24 hours.
| percentage of participants | Part 1: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20/27 mg/m² |
|---|---|---|---|
| Best Overall Response Rate (ORR) in the Response Evaluable Population | 17.1 (6.56 to 33.65) | 42.4 (29.6 to 55.9) | 52.2 (39.7 to 64.6) |
Clinical Benefit Rate is defined as the percentage of participants with a best overall response of minimal response (MR) or better, i.e., a best overall response of sCR, CR, VGPR, PR, or MR. MR was defined as outlined by European Group for Blood and Marrow Transplantation (EBMT) criteria, defined as reduction of M-protein in serum of 25% to 49% and in urine of 50% to 89%, maintained for 6 weeks.
| percentage of participants | Part 1: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20/27 mg/m² |
|---|---|---|---|
| Clinical Benefit Rate (CBR) | 31.4 (16.85 to 49.29) | 59.3 (45.7 to 71.9) | 64.2 (51.5 to 75.5) |
DOR is defined as the time from first evidence of PR or better to disease progression assessed by the IRC or death due to any cause. Patients lost to follow-up prior to disease progression or who were alive without disease progression before the analysis cutoff date were censored at the last disease assessment. Progressive disease was defined as any of the following: * An increase of M-protein in serum (absolute increase ≥ 0.5 g/dL) or urine (absolute increase ≥ 200 mg/24 hours) of \> 25% from the nadir (if not zero). * Percentage of plasma cells in bone marrow ≥ 10%. * New or increased size of bone lesions or new plasmacytomas. * Patients without measurable serum and urine M-protein: 25% increase from nadir in the difference between involved and uninvolved FLC levels and absolute increase \>10 mg/dL. * Development of hypercalcemia (corrected serum calcium \> 11.5 mg/dL) attributed solely to the proliferative disorder. Median DOR was estimated using Kaplan-Meier methods.
| months | Part 1: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20/27 mg/m² |
|---|---|---|---|
| Duration of Response (DOR) | NA (10.6 to NA) | 13.1 (7.2 to NA) | NA (NA to NA) |
Time to Progression is defined as the time from the start of treatment to IRC-determined disease progression. Patients who were lost to follow-up prior to documentation of disease progression, or who died before documentation of disease progression or who were alive and did not have documentation of disease progression before the data analysis cut-off date were censored at the last disease assessment. Median TTP was estimated using the Kaplan-Meier method.
| months | Part 1: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20/27 mg/m² |
|---|---|---|---|
| Time to Progression (TTP) | 4.6 (1.9 to 11.1) | 8.3 (6.0 to 12.3) | NA (11.3 to NA) |
Progression-free Survival (PFS) is defined as the time from start of treatment to IRC determined disease progression or death due to any cause. Patients who were lost to follow-up prior to documentation of disease progression and patients who were alive without disease progression before a data analysis cut-off date were censored at the last disease assessment. Median PFS was estimated using the Kaplan-Meier method.
| months | Part 1: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20/27 mg/m² |
|---|---|---|---|
| Progression-free Survival (PFS) | 4.6 (2.1 to 11.1) | 8.2 (6.0 to 12.3) | NA (11.3 to NA) |
Overall Survival is defined as the time from the start of study treatment to date of death due to any cause. Patients who were alive or lost to follow-up as of the data analysis cut-off date for the final OS analysis were censored at the date the patient was last known to be alive. Median OS was estimated using the Kaplan-Meier method.
| months | Part 1: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20/27 mg/m² |
|---|---|---|---|
| Overall Survival (OS) | 45.6 (28.4 to NA) | NA (33.4 to NA) | 37.3 (27.1 to NA) |
Collected over From the first dose of study medication until 30 days after the last dose or initiation of new, non-protocol therapy for MM, whichever was first; median duration of treatment was 100 days for Part 1 and 170 days for Part 2 participants.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Carfilzomib 20 mg/m² | — | 12/35 (34.3%) | 35/35 (100%) |
| Part 2: Carfilzomib 20 mg/m² | — | 18/59 (30.5%) | 59/59 (100%) |
| Part 2: Carfilzomib 20/27 mg/m² | — | 27/70 (38.6%) | 70/70 (100%) |
| Event | Part 1: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20/27 mg/m² |
|---|---|---|---|
| PneumoniaInfections and infestations | 3/35 | 6/59 | 6/70 |
| PyrexiaGeneral disorders | 2/35 | 1/59 | 3/70 |
| HypercalcaemiaMetabolism and nutrition disorders | 2/35 | 0/59 | 0/70 |
| Renal failure acuteRenal and urinary disorders | 1/35 | 2/59 | 3/70 |
| Cardiac failure congestiveCardiac disorders | 1/35 | 2/59 | 2/70 |
| Tumour lysis syndromeNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/35 | 2/59 | 0/70 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/35 | 2/59 | 1/70 |
| AnaemiaBlood and lymphatic system disorders | 0/35 | 0/59 | 2/70 |
| NeutropeniaBlood and lymphatic system disorders | 0/35 | 0/59 | 2/70 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/35 | 0/59 | 0/70 |
| Event | Part 1: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20/27 mg/m² |
|---|---|---|---|
| FatigueGeneral disorders | 22/35 | 42/59 | 38/70 |
| NauseaGastrointestinal disorders | 21/35 | 32/59 | 31/70 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 13/35 | 29/59 | 19/70 |
| AnaemiaBlood and lymphatic system disorders | 12/35 | 27/59 | 25/70 |
| VomitingGastrointestinal disorders | 15/35 | 14/59 | 14/70 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/35 | 23/59 | 21/70 |
| DiarrhoeaGastrointestinal disorders | 13/35 | 21/59 | 18/70 |
| PyrexiaGeneral disorders | 8/35 | 21/59 | 22/70 |
| Blood creatinine increasedInvestigations | 12/35 | 14/59 | 10/70 |
| LymphopeniaBlood and lymphatic system disorders | 6/35 | 20/59 | 13/70 |
Safety Population: All patients enrolled on study and who received at least 1 dose of carfilzomib.
| Age, Categorical(Participants) | Part 1: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20/27 mg/m² | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 21 | 29 | 31 | 81 |
| >=65 years | 14 | 30 | 39 | 83 |
| Sex: Female, Male(Participants) | Part 1: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20/27 mg/m² | Total |
|---|---|---|---|---|
| Female | 17 | 27 | 26 | 70 |
| Male | 18 | 32 | 44 | 94 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Part 1: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20/27 mg/m² | Total |
|---|---|---|---|---|
| 0 (Fully Active) | 15 | 29 | 23 | 67 |
| 1 (Restrictive but ambulatory) | 18 | 27 | 42 | 87 |
| 2 (Ambulatory but unable to work) | 1 | 3 | 5 | 9 |
| Missing | 1 | 0 | 0 | 1 |
| Measurable Disease Category(participants) | Part 1: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20 mg/m² | Part 2: Carfilzomib 20/27 mg/m² | Total |
|---|---|---|---|---|
| SPEP and UPEP | 3 | 6 | 11 | 20 |
| SPEP | 22 | 39 | 47 | 108 |
| UPEP | 6 | 6 | 10 | 22 |
| SFLC Only | 4 | 6 | 1 | 11 |
| IgA, by Immunoglobulin Assay Only | 0 | 2 | 0 | 2 |
| Missing | 0 | 0 | 1 | 1 |
The record gives a start of Sep 2007, a primary completion of Jan 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Carfilzomib